<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809156</url>
  </required_header>
  <id_info>
    <org_study_id>15-3056</org_study_id>
    <nct_id>NCT03809156</nct_id>
  </id_info>
  <brief_title>Upfront Combination Pulmonary Arterial Hypertension Therapy</brief_title>
  <official_title>Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of first-line combination therapy using riociguat with&#xD;
      ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, open-label, exploratory study with patients followed for&#xD;
      a period of one year. The treatment duration period in this study begins at the initiation of&#xD;
      ambrisentan plus riociguat and will continue for 12 months. Patients will come to clinic for&#xD;
      a visit at month 4 and 12. Assessments will include Right Heart Catheterization, 6 Minute&#xD;
      walk test, cardiac MRI, questionnaires and nt-Pro-BNP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2016</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Vascular resistance</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Change from baseline to month 4 and month 12 in pulmonary vascular resistance (PVR) as assessed by Right Heart Catheterization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Variables</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Change in hemodynamic variables (mPAP, RAP, CI) from baseline to month 4 and month 12 as assessed by Right Heart Catheterization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Change in echocardiographic parameters (TAPSE, RV strain, Tei index, Left ventricular Eccentricity index, RV:LV area ratio) as assessed by Echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV function</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Change from baseline to month 4 in RV function as assessed by cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-PRo-BNP</measure>
    <time_frame>4 and 12 Months</time_frame>
    <description>Change from baseline NT-PRo-BNP value from baseline to month 4 and month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Change from baseline to month 4 and month 12 in exercise capacity assessed by the 6 minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Change from baseline to month 4 and month 12 in dyspnea as assessed by study questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Change from baseline to month 4 and month 12 in quality of life as assessed by study questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Class</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Change from baseline to month 4 and month 12 in functional class as assessed by study questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Survival at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical worsening</measure>
    <time_frame>12 months</time_frame>
    <description>Time to clinical worsening over 12 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Combo Riociguat and Ambrisentan Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riociguat Oral Product and Ambrisentan Oral Product to be given in combination to de novo (untreated) patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat Oral Product</intervention_name>
    <description>Dual therapy of Riociguat and Ambrisentan at initiation of treatment.</description>
    <arm_group_label>Combo Riociguat and Ambrisentan Therapy</arm_group_label>
    <other_name>Ambrisentan Oral Product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent prior to initiation of any study mandated procedure;&#xD;
&#xD;
          2. Males or females ≥ 18 years of age i. Women of childbearing potential must have a&#xD;
             negative pre-treatment pregnancy test and must use reliable methods of contraception.&#xD;
&#xD;
             ii. Women not of childbearing potential are defined as postmenopausal (i.e.,&#xD;
             amenorrhea for at least 1 year), or documented surgically or naturally sterile.&#xD;
&#xD;
          3. Patients with symptomatic Functional Class III PAH in the following categories:&#xD;
&#xD;
             i. Idiopathic (IPAH) ii. Familial (FPAH) iii. Associated with connective tissue&#xD;
             disease iv. Associated with drugs or toxins;&#xD;
&#xD;
          4. PAH diagnosed by right heart catheterization, defined as:&#xD;
&#xD;
             i. Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg ii. PVR &gt; 3 mmHg/l/min (Wood&#xD;
             units) or &gt; 240 dyn sec cm-5 iii. Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg;&#xD;
&#xD;
          5. 150 m ≤ 6 Minute Walk Test (6MWT) distance ≤ 480 m&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. PAH associated with any other condition than those described in the inclusion criteria&#xD;
             (patients with PAH associated with portal hypertension, HIV and CHD should not be&#xD;
             included);&#xD;
&#xD;
          2. PAH associated with thyroid disorders, glycogen storage disease, Gaucher disease,&#xD;
             hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative&#xD;
             disorders and splenectomy;&#xD;
&#xD;
          3. Valvular disease with valvular lesions to be excluded by echocardiogram within 2 years&#xD;
             prior to randomization (i.e., patients with tricuspid or pulmonary insufficiency&#xD;
             secondary to PAH can be included);&#xD;
&#xD;
          4. Restrictive lung disease: total lung capacity (TLC) &lt; 60% of normal predicted value;&#xD;
&#xD;
          5. Obstructive lung disease: forced expiratory volume/forced vital capacity (FEV1/FVC) &lt;&#xD;
             0.5;&#xD;
&#xD;
          6. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C;&#xD;
&#xD;
          7. Pregnancy or breast-feeding;&#xD;
&#xD;
          8. Systolic blood pressure &lt; 95 mmHg;&#xD;
&#xD;
          9. Body weight &lt; 40 kg;&#xD;
&#xD;
         10. Hemoglobin &gt; 25% below the lower limit of the normal range;&#xD;
&#xD;
         11. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 1.5 times the&#xD;
             upper limit of normal ranges;&#xD;
&#xD;
         12. Renal insufficiency as defined by creatinine clearance &lt; 30 mL/min or on dialysis&#xD;
&#xD;
         13. Treatment with phosphodiesterase type 5 inhibitors, any prostanoid (excluding acute&#xD;
             administration during a catheterization procedure to test vascular reactivity) or with&#xD;
             any other PH specific medication;&#xD;
&#xD;
         14. Treatment or planned treatment with calcineurin-inhibitors (i.e., cyclosporine A and&#xD;
             tacrolimus), CYP2C9 and CYP3A4 inhibitors (i.e., ketoconazole, fluconazole) within 1&#xD;
             week of study start;&#xD;
&#xD;
         15. Treatment or planned treatment with nitrate drugs, short acting nitrate-containing&#xD;
             medications, alpha blockers or protease inhibitors (i.e., ritonavir);&#xD;
&#xD;
         16. Known hypersensitivity to ambrisentan, riociguat or any of their excipients;&#xD;
&#xD;
         17. Patients with any contraindication to riociguat treatment or ERA treatment&#xD;
&#xD;
         18. Patients with syncope, a rapid rate of symptom progression or with high or rising&#xD;
             nt-BNP levels in the judgment of the investigators&#xD;
&#xD;
         19. Any contraindications specified in the product monographs of either ambrisentan or&#xD;
             riociguat, including:&#xD;
&#xD;
        1. Patients at increased risk of hypotension with concomitant or underlying conditions such&#xD;
        as coronary artery disease, hypovolemia, severe left ventricular outflow obstruction or&#xD;
        autonomic dysfunction; patients with resting hypotension 2. Patients with history of&#xD;
        serious hemoptysis or patients who have previously undergone bronchial arterial&#xD;
        embolization 20. Patients with pulmonary veno-occlusive disease 21. Ongoing participation&#xD;
        in any interventional clinical studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naushad Hirani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naushad Hirani, MD</last_name>
    <phone>403 943 4759</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Marks, BN</last_name>
    <phone>(403) 943 4759</phone>
    <email>jean.marks@ahs.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peter Lougheed Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naushad Hirani, MD</last_name>
      <phone>403 943 4759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital, The Lung Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Swiston, MD</last_name>
      <phone>(604) 875 4122</phone>
      <email>swiston@mail.ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mami Okada</last_name>
      <phone>(604) 875 4111</phone>
      <phone_ext>69831</phone_ext>
      <email>mami.okada@vch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>John Swiston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambrisentan</mesh_term>
    <mesh_term>Riociguat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

